Treatment with a BTK inhibitor before SARS-CoV-2 vaccination, as well as qualitative differences for immune stimulation between vaccination and infection, may also have contributed to the blunted vaccination responses observed in patients with CLL or WM on BTK inhibitors. This evidence concerns the gene BTK and infection.